Trial · NCT00278629
Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy
NCT00278629, Phase 2, Completed, Northwestern University; results first posted 2020-07-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy. Trials, record NCT00278629. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00278629
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy
- NCT number
- NCT00278629
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 80 participants, actual
- Lead sponsor
- Northwestern University
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- hematopoietic stem cell transplantation
- First posted
- 2006-01-18
- Last updated
- 2020-07-23
- Results first posted
- 2020-07-23
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Survival | up to 5 years | Survival of participants who survived the treatment and up to 5 years post treatment. |
| Secondary | Disease Improvement - Medication Free Remission | 6 months, 1, 2, 3, 4 and 5 years post transplant | Post transplant immune medication-free remission with stable or improving neurological exam |
| Secondary | Disease Improvement - Ambulatory Assistance | pre transplant, 6 months, 1, 2, 3, 4 and 5 years post transplant | Disease Improvement - Requires No Assistance to Ambulate |
| Secondary | Change in Disability and Strength Functional Scales | Pre Transplant, 6 months, 1, 2, 3, 4 and 5 years post transplant | Change in the Medical Research Council (MRC) Scale: range is 0 (quadriplegic) - 60 (normal). |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Survival | up to 5 years | The reason that the number analyzed is different from the overall number of participants anaylyzed is because 2 patients died from non treatment related conditions that were present before the transplant. Both deaths occurred more than 100 days after the hospital discharge from treatment. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Disease Improvement - Medication Free Remission | 6 months, 1, 2, 3, 4 and 5 years post transplant | The number analyzed in one or more rows differs from the over all number because not all patients returned for follow up. | participants | NUMBER |
| SECONDARY | Disease Improvement - Ambulatory Assistance | pre transplant, 6 months, 1, 2, 3, 4 and 5 years post transplant | The number analyzed in one or more rows differs from the overall number analyzed because not all patients returned for followed up testing. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change in Disability and Strength Functional Scales | Pre Transplant, 6 months, 1, 2, 3, 4 and 5 years post transplant | The reason the number analyzed in one or more rows differs from the overall number analyzed is because not all patients returned for followed up testing. | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group22
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Survival | Hematopoietic Stem Cell Transplantation for CIDP | Treatment Survival | 66 | Participants | |
| Number of Participants With Survival | Hematopoietic Stem Cell Transplantation for CIDP | Post Treament Survival | 64 | Participants | |
| Disease Improvement - Medication Free Remission | Hematopoietic Stem Cell Transplantation for CIDP | 6 months post transplant | 48 | participants | |
| Disease Improvement - Medication Free Remission | Hematopoietic Stem Cell Transplantation for CIDP | 1 year post transplant | 48 | participants | |
| Disease Improvement - Medication Free Remission | Hematopoietic Stem Cell Transplantation for CIDP | 2 years after transplant | 47 | participants | |
| Disease Improvement - Medication Free Remission | Hematopoietic Stem Cell Transplantation for CIDP | 3 years post transplant | 45 | participants | |
| Disease Improvement - Medication Free Remission | Hematopoietic Stem Cell Transplantation for CIDP | 4 years post transplant | 39 | participants | |
| Disease Improvement - Medication Free Remission | Hematopoietic Stem Cell Transplantation for CIDP | 5 years post transplant | 35 | participants | |
| Disease Improvement - Ambulatory Assistance | Hematopoietic Stem Cell Transplantation for CIDP | pre transplant | 19 | Participants | |
| Disease Improvement - Ambulatory Assistance | Hematopoietic Stem Cell Transplantation for CIDP | 6 months post transplant | 41 | Participants |
1 to 10 of 22Source ClinicalTrials.gov
See all 22 results by groupParticipant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Hematopoietic Stem Cell Transplantation | 80 | |
| Overall Study | COMPLETED | Hematopoietic Stem Cell Transplantation | 66 | |
| Overall Study | NOT COMPLETED | Hematopoietic Stem Cell Transplantation | 14 |
Source ClinicalTrials.gov
Adverse events13
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypophosphatemia | Metabolism and nutrition disorders | Hematopoietic Stem Cell Transplantation for CIDP | 29 | 66 | 29 |
| other | Febrile Neutropenia | General disorders | Hematopoietic Stem Cell Transplantation for CIDP | 26 | 66 | 26 |
| other | Hypokalemia | Metabolism and nutrition disorders | Hematopoietic Stem Cell Transplantation for CIDP | 19 | 66 | 19 |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | Hematopoietic Stem Cell Transplantation for CIDP | 8 | 66 | 8 |
| other | Infections | Infections and infestations | Hematopoietic Stem Cell Transplantation for CIDP | 8 | 66 | 8 |
| other | Clostridium Difficile Diarrhea | Infections and infestations | Hematopoietic Stem Cell Transplantation for CIDP | 4 | 66 | 4 |
| other | Hypocalcemia | Metabolism and nutrition disorders | Hematopoietic Stem Cell Transplantation for CIDP | 5 | 66 | 5 |
| other | Hyponatremia | Metabolism and nutrition disorders | Hematopoietic Stem Cell Transplantation for CIDP | 5 | 66 | 5 |
| serious | Total Parenteral Nutrition - due to vomiting | Gastrointestinal disorders | Hematopoietic Stem Cell Transplantation for CIDP | 1 | 66 | |
| serious | Hypokalemia | Metabolism and nutrition disorders | Hematopoietic Stem Cell Transplantation for CIDP | 1 | 66 |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Hematopoietic Stem Cell Transplantation for CIDP | 2 | 66 |
| Total, other adverse events | Hematopoietic Stem Cell Transplantation for CIDP | 29 | 66 |
| Total, serious adverse events | Hematopoietic Stem Cell Transplantation for CIDP | 2 | 66 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 32594300 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00278629
GET https://conductscience.org/api/trials/v1/NCT00278629/results?page=2